Cancer screening: How good is good enough?

Journal of Clinical Oncology

Volumn 22, Issue 20, 2004, Pages 4037-4039

  Hensley, Martee L ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; TUMOR MARKER;

BLOOD EXAMINATION; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; ECHOGRAPHY; EDITORIAL; HUMAN; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; BLOOD; FEMALE; NOTE; OVARY TUMOR; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 7044222287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.129     Document Type: Editorial

References (13)

1. American Cancer Society: Cancer Facts and Figures 2003, American Cancer Society. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_ Facts_Figures_2003.asp
2. Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in stage I and II epithelial ovarian cancer: Results of two prospective randomized trials. N Engl J Med 322:1021-1027, 1990
3. Jacobs I, Bast RC Jr: The CA125 tumor-associated antigen: A review of the literature. Hum Reprod 4:1-12, 1989
4. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: A pilot randomized trial. Lancet 353:1207-1210, 1999
5. Skates SJ, Horack N, Yinhua Y, et al: Pre-operative sensitivity and specificity for early stage ovarian cancer when combining cancer antigen (CA) -125 II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixture of multivariate normal distributions. J Clin Oncol 22:4059-4066, 2004
6. Shridar V, Lee J, Pandita A, et al: Genetic analysis of early verus late stage ovarian tumors. Cancer Res 61:5895-5904, 2001
7. Xu Y, Shen Z, Wiper DW, et al: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723, 1998
8. Xu F-J, Yu Y-A, Daly L, et al: OVX1 radioimmunoassay complements CA125 for predicting the presence of residual ovarian cancer at second-look surgical surveillance procedures. J Clin Oncol 11:1506-1510, 1993
9. Dupont J, Tanwar MK, Thaler HT, et al: Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22:3330-3339, 2004
10. Zurawski V, Orjaster H, Andersen A, et al: Elevated CA125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int J Cancer 42:677-680, 1988
11. Skates SJ, Xu FJ, Yu YH, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76:2004-2010, 1995
12. Hensley ML, Robson ME, Kauff ND, et al: Pre- and post-menopausal high-risk women undergoing screening for ovarian cancer: Anxiety, risk perceptions, and quality of life. Gynecol Oncol 89:440-446, 2003
13. Schmid H-P, Riesen W, Prikler L: Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50:71-78, 2004